Reading File
analyse_media
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Here is a thorough breakdown and expansion of everything on that page from Fast Track Basic Science MBBS, supplemented with content from authoritative textbooks.
Parkinson's Disease - Complete Notes
What is It?
Parkinson's disease (PD) is a slowly progressive neurodegenerative disorder characterized by destruction of dopamine-secreting neurons, primarily in the substantia nigra and locus ceruleus.
The core problem: dopaminergic neurons (which are inhibitory) degenerate, creating an imbalance where the cholinergic pathway (excitatory) becomes dominant - this imbalance is what produces motor defects.
Pathophysiology
| Component | Role |
|---|---|
| Substantia nigra (nigrostriatal pathway) | Normal dopamine production - inhibitory |
| Striatum (caudate + putamen) | Receives dopaminergic input |
| Cholinergic pathway | Excitatory - becomes overactive when dopamine drops |
When dopaminergic neurons in the nigrostriatal pathway degenerate:
- Loss of inhibitory control on the basal ganglia
- Thalamus becomes over-inhibited
- Result: hypokinetic movement disorder (difficulty initiating and executing movement)
Lewy bodies - intraneuronal inclusions composed of misfolded alpha-synuclein protein - are the histological hallmark. Mutations in the gene for alpha-synuclein are a recognized genetic cause.
Causes
- Primary/Idiopathic - Degeneration of dopamine-secreting neurons in the nigrostriatal (dopaminergic) pathway (most common)
- Environmental toxins (e.g., MPTP, pesticides)
- Drug-induced (secondary Parkinsonism):
- Dopamine antagonists: neuroleptics (haloperidol), chlorpromazine, metoclopramide
- These block D2 receptors, mimicking dopamine deficiency
- Genetic - Mutations in the gene for alpha-synuclein (a protein involved in synaptic function)
Signs & Symptoms
The classic clinical tetrad:
| Symptom | Details |
|---|---|
| Resting (static) tremor | "Pill-rolling" tremor at rest; disappears with voluntary movement |
| Rigidity | "Lead pipe" or "cogwheel" rigidity; stiffness of all muscles |
| Bradykinesia / Hypokinesia | Slowness of movement; difficulty initiating movement |
| Postural instability | Loss of postural reflexes; contributes to festinant gait |
Additional symptoms from the page:
- Festinant gait: Patient walks in rapid, short shuffling steps leaning forward - compensating for shifted center of gravity
- Speech problems: Hypophonia (soft speech), dysarthria, and hesitancy
Non-motor symptoms (not on the page but important):
- Anosmia (often an early feature - before motor symptoms)
- Depression and anxiety
- REM sleep behavior disorder
- Autonomic dysfunction: orthostatic hypotension, constipation, urinary problems
- Dementia (15-40% of cases in later stages)
- Seborrhea, hypersalivation
Treatment
First-Line: Levodopa + Carbidopa
Levodopa is the gold standard and most effective drug.
- Levodopa is a precursor of dopamine that crosses the blood-brain barrier (dopamine itself cannot)
- It is converted to dopamine by DOPA decarboxylase in the brain
Why combine with Carbidopa (or Benserazide)?
- Carbidopa is a peripheral decarboxylase inhibitor - it does NOT cross the blood-brain barrier
- It blocks the conversion of levodopa to dopamine in peripheral tissues, so more levodopa reaches the brain
- This reduces peripheral side effects: nausea, vomiting, orthostatic hypotension
- Standard formulation: Levodopa 250 mg + Carbidopa 25 mg (Sinemet)
Other Treatments (beyond the page)
| Drug Class | Examples | Mechanism |
|---|---|---|
| MAO-B inhibitors | Selegiline, Rasagiline | Block dopamine breakdown; used early or as add-on |
| Dopamine agonists | Pramipexole, Ropinirole | Directly stimulate dopamine receptors |
| COMT inhibitors | Entacapone, Tolcapone | Prevent peripheral levodopa breakdown; prolong action |
| Anticholinergics | Benztropine, Trihexyphenidyl | Reduce cholinergic overactivity; useful for tremor |
| Amantadine | - | Anticholinergic + antiglutamatergic; helps dyskinesia |
| Deep Brain Stimulation (DBS) | Subthalamic nucleus / globus pallidus | Surgical option for advanced disease |
Levodopa Long-Term Complications
- Wearing off: Effect diminishes before next dose
- On-off phenomena: Unpredictable fluctuations between mobility and near-immobility
- Levodopa-induced dyskinesias: Involuntary movements at peak dose
- Psychiatric effects: Hallucinations, psychosis at high doses
Quick Memory Aid
TRAP = Tremor (resting), Rigidity, Akinesia/bradykinesia, Postural instability
Dopamine DOWN + Acetylcholine UP = Parkinson's (treat by raising dopamine or blocking ACh)
Sources:
- Fast Track Basic Science MBBS, p. 474 (your textbook image)
- Neuroanatomy through Clinical Cases, 3rd Ed., p. 792
- Katzung's Basic and Clinical Pharmacology, 16th Ed., Chapters 28-29
- Bradley and Daroff's Neurology in Clinical Practice
This is a shared conversation. Sign in to Orris to start your own chat.